3 ms·

If I have had Covid-19 already, do I need to get the vaccine and why?

2 points by colinprince 6y ago

rolph 6y ago
There seems to be nothing in the article, or in the references suggesting that the vaccine provides any greater advantage other than avoiding morbidity and possible mortality. There seems to be a running premise that SARS-2 infection provides short term immunity at best, based on titre of antibodies. There is no immediate way to confirm or deny such a hypothesis, other than compare SARS-1 survivors to non SARS-1 survivors that have been recently exposed to the SARS pathogen. This would provide two points of comparison spaced 17 years apart. I was infected with SARS-1 in 2003 and recently with SARS-2 during the SARS-2 infection [asymptomatic] i was tested for antibodies. the results indicated "one of the highest scores observed in my region" . 32 weeks post infection i am still providing antibodies for use in local infusion centres, and fortuitously i am a universal dOnor blood type. clearly in my case SARS-1 infection and recovery has provided protection 17 years later. I have since had long term repeated proximity contact with sars-2 positive individuals numerous times, without testing positive for the virus, and continue to provide serum. bear in mind i maintain self isolation from people not testing positive, and in one case have provided a direct transfusion to a fellow professional in a non clinical setting, and they kicked the virus to pieces in the space of a week. [redacted] ------------------------------------------------------- https://doi.org/10.1038/s41577-020-00436-4 https://doi.org/10.1038/s41577-020-00436-4 "Studies of patients who became infected with SARS-CoV in 2003 suggested that the infection induced durable T cell responses lasting for 6 years but no long-term memory B cells [9]. Importantly, these T cells were shown to cross-react with the SARS-CoV-2 virus 17 years later [10], but the extent to which they can provide protection is not known. Most importantly, the early global sharing of scientific data is vitally important to understand the complexities of the B cell and T cell responses in COVID-19 and to elucidate which immune responses provide protection from both the initial infection and reinfection."

2 points by colinprince 6y ago

There seems to be nothing in the article, or in the references suggesting that the vaccine provides any greater advantage other than avoiding morbidity and possible mortality. There seems to be a running premise that SARS-2 infection provides short term immunity at best, based on titre of antibodies. There is no immediate way to confirm or deny such a hypothesis, other than compare SARS-1 survivors to non SARS-1 survivors that have been recently exposed to the SARS pathogen. This would provide two points of comparison spaced 17 years apart. I was infected with SARS-1 in 2003 and recently with SARS-2 during the SARS-2 infection [asymptomatic] i was tested for antibodies. the results indicated "one of the highest scores observed in my region" . 32 weeks post infection i am still providing antibodies for use in local infusion centres, and fortuitously i am a universal dOnor blood type. clearly in my case SARS-1 infection and recovery has provided protection 17 years later. I have since had long term repeated proximity contact with sars-2 positive individuals numerous times, without testing positive for the virus, and continue to provide serum. bear in mind i maintain self isolation from people not testing positive, and in one case have provided a direct transfusion to a fellow professional in a non clinical setting, and they kicked the virus to pieces in the space of a week. [redacted] ------------------------------------------------------- https://doi.org/10.1038/s41577-020-00436-4 https://doi.org/10.1038/s41577-020-00436-4 "Studies of patients who became infected with SARS-CoV in 2003 suggested that the infection induced durable T cell responses lasting for 6 years but no long-term memory B cells [9]. Importantly, these T cells were shown to cross-react with the SARS-CoV-2 virus 17 years later [10], but the extent to which they can provide protection is not known. Most importantly, the early global sharing of scientific data is vitally important to understand the complexities of the B cell and T cell responses in COVID-19 and to elucidate which immune responses provide protection from both the initial infection and reinfection."